Abstract
Since no definitive cure for COVID-19 is available so far, one of the challenges against the disease is understanding the clinical features and the laboratory inflammatory markers that can differentiate among different severity grades of the disease. The aim of the present study is a comprehensive and longitudinal evaluation of SCD14-ST and other new inflammatory markers, as well as cytokine storm molecules and current inflammatory parameters, in order to define a panel of biomarkers that could be useful for a better prognostic prediction of COVID-19 mortality. SCD14-ST, as well as the inflammatory markers IL-6, IL-10, SuPAR and sRAGE, were measured in plasma-EDTA of ICU COVID-19 positive patients. In this longitudinal study, SCD14-ST resulted significantly higher in patients who eventually died compared to those who were discharged from the ICU. The results suggest that the new infection biomarker SCD14-ST, in addition to new generation inflammatory biomarkers, such as SuPAR, sRAGE and the cytokines IL-6 and IL-10, can be a useful prognostic tool associated with canonical inflammatory parameters, such as CRP, to predict SARS-CoV-2 outcome in ICU patients.
Keywords: SARS-CoV-2; SCD14-ST; immune biomarkers; prediction of disease.
【저자키워드】 SARS-CoV-2, SCD14-ST, immune biomarkers, prediction of disease., 【초록키워드】 COVID-19, Cytokine storm, Biomarker, Biomarkers, Cytokines, IL-6, severity, suPAR, Infection, inflammatory markers, CRP, cytokine, outcome, immune, Clinical features, ICU, Laboratory, longitudinal study, Patient, ICU Patients, Inflammatory marker, IL-10, prognostic, disease, predict, clinical feature, inflammatory biomarkers, COVID-19 mortality, Longitudinal evaluation, inflammatory parameters, new infection, cytokines IL-6, plasma-EDTA, COVID-19 positive patients, died, addition, the disease, significantly higher, to define, discharged, were measured, canonical, 【제목키워드】 COVID-19, prediction, Generation, New,